Table 1 Demographics and disease related information of patients.

Mean age, years ± SD

38.76 ± 12.4

43.62 ± 11.96

34.59 ± 11.20

 < 0.001^a

Sex [male], n [%]

610 [60.9%]

260 [56.2%]

350 [65.1%]

0.004^b

Single, n [%]

288 [28.8%]

61 [13.2%]

227 [38.5%]

 < 0.001^b

Educational level, n [%]

 High school and below

444 [44.4%]

223 [48.2%]

221 [41.1%]

0.024^b

 College and above

557 [55.6%]

240 [51.8%]

317 [58.9%]

Disease duration, n [%]

 < 5 yaers

579 [57.8%]

273 [59.0%]

306 [56.5%]

0.208^b

 5 to < 10 years

252 [25.2%]

106 [22.9%]

146 [27.1%]

 10 to < 15 years

92 [9.2%]

41 [8.8%]

51 [9.6%]

 ≥ 15 years

78 [7.8%]

43 [9.3%]

35 [6.5%]

Vaccinate against COVID-19

355 [35.5%]

177 [38.2%]

178 [33.1%]

0.090^b

Spotlight after the outbreak, n [%]

 Poorly controlled disease

704 [70.3%]

302 [65.2%]

402 [74.7%]

0.001^b

 SARS-CoV-2 infection

297 [29.7%]

161 [34.8%]

136 [25.3%]

Positive attitude to life, n [%]

833 [83.2%]

391 [84.4%]

442 [82.2%]

0.333^b

Preferred mode of treatment, n [%]

 MWM

459 [45.9%]

176 [38.0%]

283 [52.6%]

 < 0.001^b

 TCM

32 [3.2%]

12 [2.6%]

20 [3.7%]

 Combination of MWM and TCM

Concerns during treatment, n [%]

510 [50.9%]

275 [59.4%]

235 [43.7%]

 Poorly controlled disease

502 [50.1%]

236 [51.0%]

266 [49.4%]

0.609^b

 Expensive treatment costs

372 [37.2%]

165 [35.6%]

207 [38.5%]

 Drug side effects

127 [12.7%]

62 [13.4%]

65 [12.1%]

Stable disease after oubreak, n [%]

669 [66.8%]

292 [63.1%]

377 [70.1%]

0.019^b

If therapy affected after the break, n [%]

375 [37.5%]

169 [36.5%]

206 [38.3%]

0.560^b